DK0642581T3 - Clostridium perfringens-vacciner - Google Patents
Clostridium perfringens-vaccinerInfo
- Publication number
- DK0642581T3 DK0642581T3 DK93913200T DK93913200T DK0642581T3 DK 0642581 T3 DK0642581 T3 DK 0642581T3 DK 93913200 T DK93913200 T DK 93913200T DK 93913200 T DK93913200 T DK 93913200T DK 0642581 T3 DK0642581 T3 DK 0642581T3
- Authority
- DK
- Denmark
- Prior art keywords
- toxin
- present
- clostridium perfringens
- vaccines
- peptides
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000193468 Clostridium perfringens Species 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 1
- 101710197219 Alpha-toxin Proteins 0.000 abstract 1
- 241000193403 Clostridium Species 0.000 abstract 1
- 108010081427 Clostridium perfringens alpha toxin Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 101710124951 Phospholipase C Proteins 0.000 abstract 1
- 108010079194 Type C Phospholipases Proteins 0.000 abstract 1
- 102000014384 Type C Phospholipases Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000002776 alpha toxin Substances 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929210717A GB9210717D0 (en) | 1992-05-20 | 1992-05-20 | Clostrdium perfringens vaccines |
| GB929215655A GB9215655D0 (en) | 1992-05-20 | 1992-07-23 | Clostridium perfringens vaccines |
| PCT/GB1993/001039 WO1993023543A1 (en) | 1992-05-20 | 1993-05-20 | Clostridium perfringens vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0642581T3 true DK0642581T3 (da) | 2003-02-17 |
Family
ID=26300904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93913200T DK0642581T3 (da) | 1992-05-20 | 1993-05-20 | Clostridium perfringens-vacciner |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5817317A (da) |
| EP (1) | EP0642581B1 (da) |
| JP (1) | JP3370672B2 (da) |
| CN (1) | CN1057533C (da) |
| AT (1) | ATE226635T1 (da) |
| AU (1) | AU671838B2 (da) |
| CA (1) | CA2136230C (da) |
| DE (1) | DE69332434T2 (da) |
| DK (1) | DK0642581T3 (da) |
| ES (1) | ES2185631T3 (da) |
| GB (1) | GB2283020B (da) |
| IL (1) | IL105763A (da) |
| MX (1) | MX9302964A (da) |
| NZ (1) | NZ253189A (da) |
| PT (1) | PT642581E (da) |
| WO (1) | WO1993023543A1 (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9605222D0 (en) * | 1996-03-12 | 1996-05-15 | Secr Defence | Clostridium perfringens epsilon toxin vaccines |
| ES2276448T3 (es) * | 1997-06-20 | 2007-06-16 | Intervet International Bv | Vacuna contra clostridium perfringens. |
| CA2404356A1 (en) * | 2002-09-18 | 2004-03-18 | Canadian Inovatech Inc. | Gram-positive antibacterial composition and method for use |
| EP1765394B1 (en) | 2004-06-04 | 2009-08-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Methods for preparing immunogenic conjugates |
| MY149604A (en) * | 2005-04-18 | 2013-09-13 | Schering Plough Ltd | C.perfringens alpha toxoid vaccine |
| HUE027091T2 (en) * | 2006-03-30 | 2016-08-29 | Zoetis Services Llc | Procedures and preparations for vaccination of poultry |
| CA2649426C (en) | 2006-04-17 | 2014-04-01 | Schering-Plough Ltd. | Recombinant attenuated clostridium organisms and vaccine |
| US20100317084A1 (en) * | 2007-05-10 | 2010-12-16 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens |
| WO2009025888A2 (en) | 2007-05-10 | 2009-02-26 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety |
| WO2009046451A1 (en) | 2007-10-05 | 2009-04-09 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting a protective immune response against c. perfringens |
| WO2010045620A1 (en) | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
| US9163219B2 (en) * | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
| WO2010135563A1 (en) | 2009-05-22 | 2010-11-25 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium and methods of antigen and nucleic acid delivery |
| US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
| US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
| US8889121B2 (en) | 2010-01-22 | 2014-11-18 | The Arizona Board Of Regents For An On Behalf Of Arizona State University | Bacterium comprising a regulated rfaH nucleic acid |
| US8916162B2 (en) * | 2010-02-20 | 2014-12-23 | Alexey Gennadievich Zdanovsky | Botulinum neurotoxin antigenic compositions and methods |
| US9598697B2 (en) | 2010-05-28 | 2017-03-21 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
| WO2013049535A2 (en) | 2011-09-30 | 2013-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Influenza vaccine |
| US10174086B2 (en) | 2011-10-25 | 2019-01-08 | University Of Exeter | Vaccine |
| GB201118394D0 (en) | 2011-10-25 | 2011-12-07 | Univ Exeter | Vaccine |
| NZ700199A (en) | 2012-03-29 | 2016-08-26 | Univ Exeter | Epsilon toxin epitopes from clostridium perfringens with reduced toxicity |
| US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
| US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
| GB201322463D0 (en) * | 2013-12-18 | 2014-02-05 | Univ Exeter | Composition |
| CN104531731B (zh) * | 2014-12-15 | 2018-06-26 | 中国人民解放军军事医学科学院军事兽医研究所 | 产气荚膜梭菌α毒素人源化单链抗体7D |
| CN104531730B (zh) * | 2014-12-15 | 2018-07-17 | 中国人民解放军军事医学科学院军事兽医研究所 | 产气荚膜梭菌α毒素人源化单链抗体8B |
| WO2018067582A2 (en) | 2016-10-03 | 2018-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 env fusion peptide immunogens and their use |
| WO2018081832A1 (en) | 2016-10-31 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide fragments from filoviruses and their uses |
| US11235056B2 (en) | 2017-03-24 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Glycan-masked engineered outer domains of HIV-1 gp120 and their use |
| CN107596361B (zh) * | 2017-09-12 | 2020-08-14 | 浙江海隆生物科技有限公司 | 牛a型产气荚膜梭菌的亚单位疫苗及其制备方法和应用 |
| WO2019079337A1 (en) | 2017-10-16 | 2019-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE |
| CN108904791A (zh) * | 2018-07-20 | 2018-11-30 | 中国兽医药品监察所 | 一种产气荚膜梭菌α毒素重组亚单位疫苗及其生产方法 |
| WO2020061564A1 (en) | 2018-09-23 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use |
| AU2019368218A1 (en) | 2018-10-22 | 2021-05-27 | New York University | Recombinant GP120 protein with V1-loop deletion |
| CN109602898B (zh) * | 2018-12-28 | 2022-02-22 | 江苏省农业科学院 | 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法 |
| AU2022323509A1 (en) | 2021-08-03 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
| CN114621963A (zh) * | 2022-03-11 | 2022-06-14 | 牧原食品股份有限公司 | 一种猪魏氏梭菌a型的亚单位疫苗及其制备 |
| WO2023192835A1 (en) | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Base-covered hiv-1 envelope ectodomains and their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
| US5200318A (en) * | 1992-05-13 | 1993-04-06 | Miles Inc. | Diagnosis of IDDM with a panel of immunoreagents |
-
1993
- 1993-05-20 US US08/341,538 patent/US5817317A/en not_active Expired - Lifetime
- 1993-05-20 ES ES93913200T patent/ES2185631T3/es not_active Expired - Lifetime
- 1993-05-20 NZ NZ253189A patent/NZ253189A/en not_active IP Right Cessation
- 1993-05-20 AT AT93913200T patent/ATE226635T1/de not_active IP Right Cessation
- 1993-05-20 PT PT93913200T patent/PT642581E/pt unknown
- 1993-05-20 WO PCT/GB1993/001039 patent/WO1993023543A1/en active IP Right Grant
- 1993-05-20 CN CN93107585A patent/CN1057533C/zh not_active Expired - Lifetime
- 1993-05-20 MX MX9302964A patent/MX9302964A/es unknown
- 1993-05-20 JP JP52002593A patent/JP3370672B2/ja not_active Expired - Fee Related
- 1993-05-20 GB GB9422512A patent/GB2283020B/en not_active Revoked
- 1993-05-20 IL IL10576393A patent/IL105763A/xx not_active IP Right Cessation
- 1993-05-20 DK DK93913200T patent/DK0642581T3/da active
- 1993-05-20 DE DE69332434T patent/DE69332434T2/de not_active Expired - Fee Related
- 1993-05-20 EP EP93913200A patent/EP0642581B1/en not_active Expired - Lifetime
- 1993-05-20 CA CA002136230A patent/CA2136230C/en not_active Expired - Fee Related
- 1993-05-20 AU AU43342/93A patent/AU671838B2/en not_active Ceased
-
1996
- 1996-10-04 US US08/725,518 patent/US5851827A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69332434T2 (de) | 2003-06-26 |
| WO1993023543A1 (en) | 1993-11-25 |
| EP0642581B1 (en) | 2002-10-23 |
| CA2136230C (en) | 2008-11-18 |
| GB2283020B (en) | 1996-05-01 |
| IL105763A0 (en) | 1993-09-22 |
| CA2136230A1 (en) | 1993-11-25 |
| GB2283020A (en) | 1995-04-26 |
| AU671838B2 (en) | 1996-09-12 |
| JP3370672B2 (ja) | 2003-01-27 |
| AU4334293A (en) | 1993-12-13 |
| GB9422512D0 (en) | 1995-01-04 |
| MX9302964A (es) | 1995-01-31 |
| DE69332434D1 (de) | 2002-11-28 |
| NZ253189A (en) | 1996-08-27 |
| CN1057533C (zh) | 2000-10-18 |
| US5851827A (en) | 1998-12-22 |
| IL105763A (en) | 2005-11-20 |
| JPH07506725A (ja) | 1995-07-27 |
| EP0642581A1 (en) | 1995-03-15 |
| ATE226635T1 (de) | 2002-11-15 |
| ES2185631T3 (es) | 2003-05-01 |
| CN1084407A (zh) | 1994-03-30 |
| US5817317A (en) | 1998-10-06 |
| PT642581E (pt) | 2003-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE226635T1 (de) | Clostridium perfringens impfstoffe | |
| DE69840195D1 (de) | Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 | |
| DK0853487T3 (da) | Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus | |
| DE69532760D1 (de) | Mittel zur verabreichung von antigenen | |
| ATE171216T1 (de) | Expression und reinigung von rekombinantem, löslichem gewebefaktor | |
| DK0618813T3 (da) | Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine | |
| NO852567L (no) | Thymopentinanaloger og fremgangsmmaate for deres fremstilling. | |
| DK162421C (da) | Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen | |
| HUP9802320A2 (hu) | Makrolidok, eljárás előállításukra és makrolidokat tartalmazó gyógyszerkészítmények | |
| ES2009588A6 (es) | Un metodo para la preparacion de un polipeptido. | |
| DE69231705D1 (de) | Gag-Env Fusion-Antigen aus HIV | |
| EA200300438A1 (ru) | Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение | |
| FR2694938B1 (fr) | Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant. | |
| KR950701683A (ko) | 클로스트리디움 퍼프린겐스 백신(Clostridium perfringens wvaccines) | |
| ATE197609T1 (de) | Verfahren zur unterdrückung der immunantwort durch gentherapie | |
| NO962927D0 (no) | Hestearteritt-virus peptider, antistoffer og deres anvendelse i en diagnostisk test | |
| EP1137433A2 (en) | Pharmaceutical compositions containing protein-disulfide isomerases | |
| ATE305941T1 (de) | Impfstoff | |
| GR1000021B (el) | Αντιπροσωπευτικο προιον ανοσιογενους ανασυνδυαζομενης ζυμης & μεθοδος καθαρισμου της. | |
| IT1263913B (it) | Composti terapeuticamente attivi, utili per il trattamento di malattieconnesse con alterata funzionalita' del sistema immunitario, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |